Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.48 |
| ▸ | CA2 | P00918 | 4/20 | 0.48 |
| ▸ | ACHE | P22303 | 4/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.46 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 4/20 | 0.42 |
| ▸ | DRD3 | P35462 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | HTR1D | P28221 | 1/20 | 0.40 |
| ▸ | HTR1B | P28222 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2730699 | 1.00 | CA1 (0.48) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL1743661 | 1.00 | CA1 (0.48) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL3339874 | 0.90 | CA1 (0.43) | CA1CA2ADRB3DRD2DRD3 | |
| SCHEMBL1337530 | 0.82 | DRD2 (0.60) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL4781124 | 0.81 | DRD2 (0.45) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL17478336 | 0.79 | CA1 (0.50) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL28888447 | 0.79 | CA1 (0.50) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL20722885 | 0.79 | CA1 (0.50) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL20722746 | 0.79 | CA1 (0.50) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL1741607 | 0.79 | CA1 (0.50) | CA1CA2ACHEMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2632465-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2015-12-30 | — | — | EP | disclosed |
| EP-2632465-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2013-09-04 | — | — | EP | disclosed |
| US-20130225561-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME LLC | 2013-08-29 | — | — | US | disclosed |
| WO-2012058116-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225561-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, KCNJ1, KCNJ2 | CA1 3014/4885CA2 1341/4885ACHE 4836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.